THE CLIENT

MACVIA ARIA via KYomed INNOV

THE CHALLENGE

Allergic rhinitis is among the most common diseases in the world and affects as much as 20% of the European population. The disease is present in all age groups and often starts at a young age. Allergic rhinitis often impairs social life, work and school performance.

Peercode colleagues Michiel van Eerd and Govert de Vries are co-authors of several international peer-reviewed scientific articles published by the MACVIA ARIA consortium (an Asthma and Rhinitis NGO).

THE APPROACH

With the MASK-air from MACVIA-ARIA, you get daily insight into the symptoms of allergic rhinitis (also called hay fever), asthma and your medication use. The app is easy to use, and combines practicality with good scientific practice, having been developed with a global team of world leading allergy clinicians.
Tracking the daily symptoms and medication use allows the user to see how well the treatment is working, identify any patterns in the symptoms and therefore take control of the disease, and improve communication with a doctor or pharmacist.

The results are shown in easy to read graphs, allowing to view the symptom experience over time, in days, months, or years.
The diary has an optional reminder function to help the user remember to track and treat the symptoms, allowing to set a reminder every day or twice a day. If the user records symptoms that suggest the allergic rhinitis is uncontrolled for 3 days in a row (or more), the diary will alert to this fact. This information can be shared with your doctor or pharmacist.
The diary also includes a geo localization function that, in the future, will permit the app to allow the user to compare the symptom score with other allergy sufferers in an area, or alert the user if an allergy has reported suffering from will soon be arriving in an area!

The MASK-air App is available in more than 20 languages for iOS and Android. Terms of Use / Privacy Policy and the labeling are available.

See also the publication "Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - Reference Site Twinning (EIP on AHA)".